Therapeutic | Reslizumab |
Target | IL5 |
Heavy Chain | EVQLVESGGGLVQPGGSLRLSCAVSGLSLTSNSVNWIRQAPGKGLEWVGLIWSNGDTDYNSAIKSRFTISRDTSKSTVYLQMNSLRAEDTAVYYCAREYYGYFDYWGQGTLVTVSS |
Light Chain | DIQMTQSPSSLSASVGDRVTITCLASEGISSYLAWYQQKPGKAPKLLIYGANSLQTGVPSRFSGSGSATDYTLTISSLQPEDFATYYCQQSYKFPNTFGQGTKVEVK |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G4 |
Highest Clinical Trial (June '19) | Approved |
Estimated Status (June '19) | Active |
Recorded Developmental Technology | na |
INN Year Proposed | 2001 |
INN Year Recommended | 2002 |
Companies Involved | Celltech R&D, Schering-Plough, Allergy and Asthma Clinical Research, Celltech R&D, Teva Pharmaceutical Industries |
Conditions Approved | Asthma |
Conditions Active | Sinusitis, Churg-Strauss syndrome |
Conditions Discontinued | Oesophagitis |
Notes |